Your browser doesn't support javascript.
loading
Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension.
Peixoto, Andreia; Fernandes, Elisabete; Gaiteiro, Cristiana; Lima, Luís; Azevedo, Rita; Soares, Janine; Cotton, Sofia; Parreira, Beatriz; Neves, Manuel; Amaro, Teresina; Tavares, Ana; Teixeira, Filipe; Palmeira, Carlos; Rangel, Maria; Silva, André M N; Reis, Celso A; Santos, Lúcio Lara; Oliveira, Maria José; Ferreira, José Alexandre.
Afiliación
  • Peixoto A; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Fernandes E; New Therapies Group, INEB-Institute for Biomedical Engineering, Porto, Portugal.
  • Gaiteiro C; Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.
  • Lima L; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal.
  • Azevedo R; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Soares J; Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.
  • Cotton S; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal.
  • Parreira B; Biomaterials for Multistage Drug and Cell Delivery, INEB-Institute for Biomedical Engineering, Porto, Portugal.
  • Neves M; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Amaro T; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Tavares A; Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.
  • Teixeira F; Glycobiology in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.
  • Palmeira C; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Rangel M; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal.
  • Silva AM; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Reis CA; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Santos LL; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Oliveira MJ; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Ferreira JA; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal.
Oncotarget ; 7(39): 63138-63157, 2016 Sep 27.
Article en En | MEDLINE | ID: mdl-27542232
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Glicosilación Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Oncotarget Año: 2016 Tipo del documento: Article País de afiliación: Portugal
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Glicosilación Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Oncotarget Año: 2016 Tipo del documento: Article País de afiliación: Portugal